Low immunogenicity of emicizumab in persons with haemophilia A

INTRODUCTION: Emicizumab is a humanised, bispecific monoclonal antibody mimicking the cofactor function of activated factor (F)VIII. It is indicated for routine prophylaxis of bleeding episodes in persons with haemophilia A (PwHA) with/without FVIII inhibitors. AIM: To evaluate the development of an...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmitt, Christophe, Emrich, Thomas, Chebon, Sammy, Fernandez, Elena, Petry, Claire, Yoneyama, Koichiro, Kiialainen, Anna, Howard, Monet, Niggli, Markus, Paz‐Priel, Ido, Chang, Tiffany
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292930/
https://www.ncbi.nlm.nih.gov/pubmed/34480814
http://dx.doi.org/10.1111/hae.14398

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292930/
https://www.ncbi.nlm.nih.gov/pubmed/34480814
http://dx.doi.org/10.1111/hae.14398

Ejemplares similares